InvestorsHub Logo
icon url

TiltMyBrain

11/02/18 4:44 PM

#195770 RE: flipper44 #195769

I agree. I doubt that the UCLA abstract will move the price but should give us more clues to efficacy to chew on
icon url

reg2015

11/02/18 4:56 PM

#195772 RE: flipper44 #195769

Thank you flipper44 for taking the time and explaining your opinions on what may occur on Nov. 5 when the abstract is released, but not in its entirety. Also that LBA is most likely not on the table also. I can rest better now this weekend. There certainly seems to be a coordinated effort to keep the pps at or below $.21 but this has been talked to death already by this board. I thank everyone here who have posted so many opinions. I have read a majority of them and have learned enough to receive a MS in FDA trials, I think, LOL. Peace Reg 2015
icon url

scotty3371

11/02/18 5:21 PM

#195774 RE: flipper44 #195769

Is there ever any sarcoma news with direct? Seems to show efficacy.
icon url

learningcurve2020

11/02/18 9:17 PM

#195788 RE: flipper44 #195769

Powers likely realizes the real money is here on this board so will not release anything interesting.
icon url

marzan

11/03/18 9:51 AM

#195802 RE: flipper44 #195769

flipper, what do they compare with the addition of poly-iclc? if it is DcVaxL, then they must list some data on DcVaxL to compare with. And we can see how that L data compared with historical controls oe even the helmet. So, this Nov 5th will lift the pps, imo.
icon url

MI Dendream

11/03/18 4:44 PM

#195823 RE: flipper44 #195769

Hi Flip,

I have been away for a long time and have little capacity to keep up. I agree with your assessment that the study ends when the last patient crosses three years. I believe they would need to send protocol amendments to all IRBs for approval otherwise. This is quite challenging and time consuming, so most companies just work on an extension study and start fresh.

They don’t need to have submitted an LBA in order to advantage of the medical press at SNO. They can still utilize the PR contacts from the meeting to send out a top line press release and have the booth available to address questions from the medical community. This would still allow them to avoid encore presentation challenges at the next meeting of choice. The timing is tight for this should they have chosen to wait until the very last runner crossed the line. I am think data release associated with SNO is about Fitty-fitty.

MI Dendream